Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medartis Holding AGXSWX:MED -1.24%87 3-Year EBITDA Growth Rate is 54.90% as of Dec. 2025, which is 690% above its 10-year median of 6.95. GuruFocus rates XSWX:MED with a GF Score™ of 87/100 and a GF Value™ of CHF108.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Medartis Holding AG ranks better than 90.3% on this metric.
During the past 12 months, Medartis Holding AG's average EBITDA Per Share Growth Rate was 51.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medartis Holding AG was 54.90% per year. The lowest was -12.30% per year. And the median was 6.95% per year.
Medartis Holding AG (XSWX:MED) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medartis Holding AG 3-Year EBITDA Growth Rate Related Terms
XSWX:MED vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Medartis Holding AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's 3-Year EBITDA Growth Rate falls into.
Medartis Holding AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.90% mean?
Medartis Holding AG (XSWX:MED) has a 3-Year EBITDA Growth Rate of 54.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medartis Holding AG and its competitors. This is 690% above median its historical median of 6.95. According to the industry distribution chart, Medartis Holding AG ranks #67 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 9.7%.
Is Medartis Holding AG's 3-Year EBITDA Growth Rate too high?
Medartis Holding AG's current 3-Year EBITDA Growth Rate of 54.90% is 690% above median its 10-year median of 6.95. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Medartis Holding AG's value of 54.90% is 577.8% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #67 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medartis Holding AG has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #67 out of 691 companies for 3-Year EBITDA Growth Rate. This places Medartis Holding AG in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Medartis Holding AG's value of 54.90% is 577.8% above this benchmark. While the company's 10-year median is 6.95 vs. the industry median of 8.10, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current 3-Year EBITDA Growth Rate of 54.90% is 577.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medartis Holding AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current 3-Year EBITDA Growth Rate is 54.90%, which is 690% above median its own 10-year median of 6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF108.15, compared to a current price of CHF87.80 — trading 18.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 54.90%, which is 690% above median its 10-year median of 6.95 and 577.8% above the Medical Devices & Instruments industry median of 8.10. Medartis Holding AG's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current 3-Year EBITDA Growth Rate is 54.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF87.80 is trading 18.8% below its estimated GF Value™ of CHF108.15.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
3-Year EBITDA Growth Rate: 54.90% (690% above median its 10-year median of 6.95)
GF Value™: CHF108.15 vs. price of CHF87.80 (18.8% below fair value)
Industry Position: 577.8% above the Medical Devices & Instruments median (#67 of 691)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
87GF Score
Get the complete analysis for XSWX:MED
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
